Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00479258 · ClinicalTrials.gov registry record · Phase 3

Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents

A Phase 3 study, sponsored by Pfizer.

Terminated
Registry status
Phase 3
Development phase
2
Enrollment target

NCT00479258 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00479258, a Phase 3 study, was terminated before completion, sponsored by Pfizer.

TERMINATED
Registry status
Phase 3
Development phase
2 participants
Enrollment target

Study Summary

To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.

Interventions

  • DRUG Inhaled insulin (Exubera)
  • DRUG Subcutaneous Insulin (subject's prescribed)

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2007-10
Est. Completion 2007-10
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00479258

The ClinicalTrials.gov registry entry for NCT00479258 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Inhaled insulin (Exubera) is the first listed.

NCT00479258 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00479258 about?

NCT00479258 is a clinical study titled "Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents". To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.

What is the current status of trial NCT00479258?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2007-10. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00479258?

The interventions under investigation include: Inhaled insulin (Exubera) (DRUG), Subcutaneous Insulin (subject's prescribed) (DRUG).

Who is sponsoring clinical trial NCT00479258?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.